Compare ROIV & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | FTAI |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Corporate Leasing Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 20.5B |
| IPO Year | 2021 | 2014 |
| Metric | ROIV | FTAI |
|---|---|---|
| Price | $34.40 | $189.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $28.94 | ★ $274.67 |
| AVG Volume (30 Days) | ★ 7.1M | 1.2M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | N/A | ★ 1537.50 |
| EPS | N/A | ★ 2.42 |
| Revenue | $8,260,000.00 | ★ $2,507,409,000.00 |
| Revenue This Year | N/A | $32.73 |
| Revenue Next Year | $744.61 | $51.41 |
| P/E Ratio | ★ N/A | $78.55 |
| Revenue Growth | N/A | ★ 44.53 |
| 52 Week Low | $12.28 | $148.43 |
| 52 Week High | $37.97 | $323.51 |
| Indicator | ROIV | FTAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 37.08 |
| Support Level | $33.01 | $179.11 |
| Resistance Level | $35.70 | $232.85 |
| Average True Range (ATR) | 1.12 | 9.19 |
| MACD | -0.29 | -1.81 |
| Stochastic Oscillator | 20.61 | 7.13 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.